Accrual Delayed in Adjuvant Bevacizumab Trial
نویسندگان
چکیده
منابع مشابه
Accrual delayed in adjuvant bevacizumab trial.
Researchers have temporarily halted accrual to a trial of bevacizumab (Avastin) and two chemotherapy regimens for early-stage colon cancer after they found an unexpected number of non-cancer-related deaths in one of the study arms. The data safety monitoring board (DSMB) recommended that enrollment be delayed until 60-day mortality data could be collected and reviewed for all patients currently...
متن کاملClinical Trial Accrual: Obstacles and Opportunities
Less than 2% of patients diagnosed with cancer participate in a clinical trial in the United States (1). Gynecologic oncology patients do not appear to participate in trials with any more frequently than other cancer types. While gains in progression free survival have continued to improve overall life span for women with advanced gynecologic cancers, more cures have not been realized. Clinical...
متن کاملAccrual strategies for phase I trials with delayed patient outcome.
Phase I dose-finding trials typically are conducted using adaptive rules that select dose levels for successive patient cohorts based on the outcomes of patients treated previously in the trial. When patient outcome cannot be observed immediately after treatment, the problem arises of how to deal with new patients while waiting to observe the current patient cohort's outcomes. We consider two a...
متن کاملBevacizumab as an Adjuvant in Management of Glaucoma
Vascular endothelial growth factor is a 46-kDa homodimeric glycoprotein first identified in highly vascularized tumors in 1983.9 Four VEGF isoforms (VEGF121, VEGF165, VEGF189, and VEGF206) have been identified, which are generated by alternative mRNA splicing from the same gene.10 VEGF165 is the most abundant molecular species in the majority of tissues.10 It is a potent angiogenic stimulator, ...
متن کاملComplications in Using Automated Methods to Increase Clinical Trial Accrual
Purpose: This paper reports on the issues involved in improving accruals for cancer-related clinical trials. Clinical trials aim to determine the efficacy of novel therapies and must be conducted before new medical treatments become available to the public. In order for the clinical trial to be successful, a predetermined number of patients with an appropriate set of medical conditions must be ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JNCI: Journal of the National Cancer Institute
سال: 2006
ISSN: 1460-2105,0027-8874
DOI: 10.1093/jnci/djj148